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965with the emergence of smaller vascular sheaths and catheters
and less intensive antithrombotic regimens, it remains a major
clinical burden. Major bleeding has been identiﬁed as an
independent predictor of mortality in a number of observa-
tional and randomized studies.
The radial approach has been associated with >50%
relative reduction in bleeding and access site complications
compared with the standard femoral approach in various
clinical scenarios (2–4). In 2 recent large randomized clinical
trials, the radial approach showed better clinical beneﬁt (and
a signiﬁcant reduction in 30-day mortality) than the femoral
approach in patients with acute coronary syndromes (5,6).
However, these studies had several limitations. In the
STEMI population of the RIVAL (RadIal Vs. femorAL)
trial, only 74% of patients underwent primary PCI (7). In
the RIFLE-STEACS (RadIal versus FemoraL randomizEd
investigation in ST-Elevation Acute Coronary Syndrome)
trial, patients with cardiogenic shock were included. In both
studies, investigators also included a number of patients after
thrombolysis and with symptom duration up to 24 h.
Furthermore, the experience of operators with the radial
approach was highly variable and the crossover rate from
radial to femoral approach varied from 5.3% to 9.6%. Not all
patients involved in both studies met class of recommen-
dation criteria for primary PCI and Level of Evidence: IA
according to current North American and European
guidelines for STEMI (8,9).
Our study was designed to compare the clinical outcomes
between the radial and femoral approach in patients
presenting with acute STEMI, within 12 h of symptom
onset, in high-volume experienced centers proﬁcient in both
access sites.Methods
Study design and endpoints. The STEMI-RADIAL
(ST Elevation Myocardial Infarction treated by RADIAL
or femoral approach) trial was a randomized, national,
multicenter, parallel group trial. Patients that were admitted
with an acute STEMI, within 12 h of symptom onset, and
referred for an invasive approach with the ability to use both
access sites were eligible for inclusion. Written informed
consent was obtained in the catheterization laboratory
immediately prior to the invasive procedure. The operators
performed randomization with personal password through
computerized web system.
The primary endpoint was the cumulative incidence of
major bleeding and vascular access site complications
requiring intervention at 30 days. The net adverse clinical
events (NACEs) were deﬁned as a composite of death,
myocardial infarction (MI), stroke, and major bleeding/
vascular complications. Secondary endpoints included major
adverse cardiovascular events (deﬁned as a composite of
death, MI, and stroke), technical success, access site failure,
procedural and ﬂuoroscopy times, contrast utilization,
intensive care unit stay, and all-cause mortality at 6 months.Local ethics committees of each
participating center approved this
study. Exclusion criteria were
cardiogenic shock or inability to
obtain written informed consent,
prior aortobifemoral bypass, ab-
sence of bilateral radial or femo-
ral artery pulses, participation in
another ongoing clinical trial,
negative Allen’s test or Barbeau
test type D curve (10), and treat-
ment with oral anticoagulants. The study was registered
as a clinical trial (NCT1136187). Following 50% pati-
ent enrollment, an independent data safety monitoring
board reviewed the blinded data and recommended trial
completion.
Population and procedures. All randomized eligible
patients undergoing invasive procedure at 4 high-volume,
24/7 PCI centers were pre-treated during the ﬁrst medical
contact with acetylsalicylic acid, a 600-mg loading dose
of clopidogrel, and a bolus of unfractionated heparin
70 IU/kg or 5,000 IU. Additional unfractionated heparin
was added during the procedure according to activated
clotting time with the aim to achieve an activated clotting
time 250 s. The use of glycoprotein IIb/IIIa inhibitors,
thromboaspiration, and the individual PCI strategy
(i.e., pre-dilation, direct stenting, and post-dilation) was left
to operators’ discretion. Anticoagulants were stopped at the
end of the procedure, whereas dual antiplatelet treatment
was recommended for 12 months after the index event.
In the case of radial approach, the vascular sheath was
removed at the end of the procedure and hemostasis was
achieved with a compressive device TR Band (Terumo,
Tokyo, Japan), as previously reported (11). In the case of
femoral approach, the use of arterial closure device or manual
compression was applied according to local practice.
Deﬁnitions and data collection. STEMI patients were
deﬁned as having chest pain for at least 20 min with the
following electrocardiography changes: ST-segment eleva-
tion 2 mm in 2 continuous precordial leads or 1 mm in 2
limb leads, new left bundle branch block, or electrocardi-
ography changes compatible with true posterior MI. The
major bleeding deﬁnition was based on the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents
in Acute Myocardial Infarction Trial) criteria (12). Due to
the fact that small hematomas do not signiﬁcantly affect
mortality, only hematomas >15 cm were recorded (13).
Based on the EASY (EArly Discharge After Transradial
Stenting of CoronarY Arteries) classiﬁcation for transradial
PCI, this size corresponds to a grade >2 (14). Moreover,
these hematomas generally lead to unplanned diagnostic
examination and prolonged hospitalization, and could be
associated with the risk of antiplatelet discontinuation and
the need for additional treatments (6). Access site compli-
cations were deﬁned as pseudoaneurysms requiring closure,
periprocedural access site bleeding requiring anticoagulation
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966reversal, arteriovenous ﬁstulas, and access site complications
requiring surgical or percutaneous intervention.Death included
all-cause mortality. Stroke was deﬁned as the occurrence of
a new neurologic deﬁcit, lasting >24 h, and considered of
vascular origin. Interventional cardiologists performing proce-
dures in this trial were high-volume operators (>200 PCIs/
year) who initially had been trained to the femoral approach
with current practice in high-volume radial centers (>80%
cases/year).
All data were recorded into a web-based system and
collected in a central database. The locked database was then
transferred to the Quebec Heart and Lung Institute
Research Centre for independent data analysis. Clinical
follow-up at 30 days was obtained in all patients. Late
follow-up data were obtained from the referring physicians
or through telephone contact with the patients or a close
relative. Information on vital status at 6 months for patients
lost to follow-up was obtained from the Institute of Health
Information and Statistics of the Czech Republic.
Statistical analysis. The sample size was calculated to
demonstrate the superiority of the radial approach compared
with the femoral approach in terms of major bleeding
and access site complications. Based on our previous expe-
rience and on the incidence of major bleeding and access siteFigure 1 Study Flow Chart
In the STEMI-RADIAL trial, 707 patients were randomized and follow-up was completed in
elevation myocardial infarction.complications in the HORIZONS-AMI trial, we antici-
pated a reference event rate of 6.5%. Based on this rate, 700
patients were required to detect a 70% relative reduction
in the primary endpoint, with an 80% power and an alpha
level of 0.05. All analyses were performed on an intention-to-
treat basis. Categorical variables were presented as numbers
and percentages, and continuous variables as mean  SD or
median (interquartile range). Baseline and procedural char-
acteristics as well as event rates in the 2 treatment groups
were compared using the Fisher exact test or chi-square test
for categorical variables, and the Student t test for continuous
variables or Wilcoxon rank sum test as required. Survival
curves were constructed using Kaplan-Meier techniques, and
comparisons between groups were done using the log-rank
test. A p value <0.05 was considered signiﬁcant. Statistical
analyses were performed using JMP software, version 9.0
(SAS Institute Inc., Cary, North Carolina).Results
Patients and procedures. Between October 2009 and
February 2012, 707 patients with an STEMI were
randomly assigned to PCI via the radial (n ¼ 348) or
femoral (n ¼ 359) approach within 12 h of symptoms onset100% at 30 days. PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
Table 1 Baseline Characteristics
Overall
(n ¼ 707)
Radial
(n ¼ 348)
Femoral
(n ¼ 359) p Value
Age, yrs 62.1  11.5 62.7  11.7 61.5  11.2 0.16
Male 546 (77%) 262 (75%) 284 (79%) 0.24
Height, cm 172  9 172  9 173  8 0.48
Weight, kg 84  15 85  16 83  14 0.056
BMI, kg/m2 28  4 29  4 28  4 0.0065
Killip class 1 619 (88%) 296 (85%) 323 (90%) 0.14
2 68 (9.6%) 40 (11%) 28 (7.8%)
3 20 (2.8%) 12 (3.4%) 8 (2.2%)
Hypertension 433 (61%) 227 (65%) 206 (57%) 0.037
Dyslipidemia 271 (38%) 133 (38%) 138 (38%) 1.00
Diabetes 146 (21%) 78 (22%) 68 (19%) 0.27
Current smoker 363 (51%) 166 (48%) 197 (55%) 0.060
Previous MI 75 (11%) 32 (9.2%) 43 (12%) 0.27
Previous PCI 51 (7.2%) 27 (7.8%) 24 (6.7%) 0.66
Previous CABG 6 (0.8%) 3 (0.9%) 3 (0.8%) 1.00
Previous stroke 31 (4.4%) 17 (4.9%) 14 (3.9%) 0.58
Symptoms to balloon, min 213 (155–296) 215 (157–301) 210 (150–293) 0.28
Door to balloon, min 31  11 32  12 31  11 0.31
Artery puncture-to-balloon time, min 17  9 17  8 16  9 0.36
Inferior MI 332 (47%) 162 (47%) 170 (47%) 0.88
Lateral MI 95 (13%) 49 (14%) 46 (13%) 0.66
Anterior MI 288 (41%) 139 (40%) 149 (42%) 0.70
Posterior MI 5 (0.7%) 3 (0.9%) 2 (0.6%) 0.68
New LBBB 1 (0.1%) 1 (0.3%) 0 (0%) 0.49
Values are mean  SD, n (%), or median (interquartile range).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; LBBB ¼ left bundle branch block; MI ¼myocardial infarction; PCI ¼ percutaneous
coronary intervention.
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967in 4 different centers (Fig. 1). Baseline demographic char-
acteristics were similar in the 2 groups except that more
patients in the radial group had hypertension (Table 1).
Median age was 62 years, and 23% of patients were female.
Clinical and angiographic features were well matched in the
2 groups. The infarct vessel was the left anterior descending
artery in 41% of the cases and initial Thrombolysis In
Myocardial Infarction (TIMI) ﬂow grade 0 or 1 was
observed in 65% of patients in both groups (Table 2). There
were no signiﬁcant differences in total ischemic time, in
door-to-balloon time, or in total procedural and ﬂuoroscopy
times; 6-F sheaths were used in 75% of the cases and 5-F in
25% of the cases. The overall rate of crossover was 3.7% in
the radial group versus 0.6% in the femoral group (p ¼
0.003). Left radial approach was the default access site at 1
site (37% of patients). Crossover to femoral from right radial
approach was 5.0% compared with 1.6% from the left radial
approach (p ¼ 0.14). All crossovers were caused by vessel
tortuosities or loops, which would have induced delays in the
procedures. Thrombectomy was performed in less than one-
third of patients, and glycoprotein IIb/IIIa inhibitors were
used in 45% of patients in both groups. Pre-treatment with
acetylsalicylic acid (99%) and clopidogrel (>98%) was
similar in the 2 groups. Post-PCI TIMI ﬂow grade 3 was
present in 92% of both groups, and the mean total heparin
dose administered was 104  32 IU/kg. Closure devices
were used in 38% of femoral cases.We used Angioseal devices(Kensey Nash, Exton, Pennsylvania) in 97.5%, Femoseal
(St. Jude, St. Paul, Minnesota) in 2.2%, and Femostop
(St. Jude) in 0.3% (1 case). In the femoral group, there was no
difference in bleeding and vascular complications between
patients with or without vascular closure devices (Online
Table 1). Contrast volume consumption was signiﬁcantly
lower in the radial group (170  71 ml vs. 182  60 ml;
p ¼ 0.01).
Clinical outcomes. Follow-up at 30 days and at 6 months
was obtained in all patients. Major bleeding and vascular
complications were signiﬁcantly lower in the radial group
compared to the femoral group (1.4% vs. 7.2%; p ¼ 0.0001)
(Fig. 2). Individual components of major bleeding including
gastrointestinal bleeding, hemoglobin drop with and
without overt bleeding, hematoma >15 cm, and transfusion
and vascular complications are summarized in Figure 3.
There was no intracranial, intraocular, or retroperitoneal
bleeding in any group. The patients who had hemoglobin
drop 3 g/dl were signiﬁcantly different to those who had
hematoma >15 cm (p < 0.0001). Of 13 patients who had
major bleeding, only 5 had hematoma >15 cm, and of 21
patients who had hematoma >15 cm, only 5 had hemo-
globin drop 3 g/dl. The intensive care unit stay was
signiﬁcantly shorter in the radial group compared with the
femoral group (p ¼ 0.0016) (Table 3).
At 30 days, the NACE rate was signiﬁcantly lower in
the radial group compared with the femoral group (4.6%
Table 2 Procedural Characteristics
Overall
(n ¼ 707)
Radial
(n ¼ 348)
Femoral
(n ¼ 359) p Value
0-vessel disease 26 (3.7%) 13 (3.7%) 13 (3.6%) 0.93
1-vessel disease 354 (50%) 175 (50%) 179 (50%)
2-vessel disease 215 (30%) 108 (31%) 107 (30%)
3-vessel disease 112 (16%) 52 (15%) 60 (17%)
2 vessels 327 (46%) 160 (46%) 167 (47%) 0.94
Culprit
RCA 308 (45%) 153 (46%) 155 (45%) 0.56
LMCA 7 (1.0%) 2 (0.6%) 5 (1.4%)
LAD 282 (41%) 135 (40%) 147 (42%)
Cx 86 (13%) 46 (14%) 40 (12%)
Sheath size
5-F 184 (26%) 88 (25%) 96 (27%) 0.20
6-F 520 (74%) 260 (75%) 260 (72%)
7-F 3 (0.4%) 0 (0%) 3 (0.8%)
Crossover 15 (2.1%) 13 (3.7%) 2 (0.6%) 0.0034
Stenting 634 (90%) 313 (90%) 321 (89%) 0.90
BMS 1.1  0.7
1 (1.0–1.0)
1.0  0.7
1 (1.0–1.0)
1.1  0.7
1 (1.0–1.0)
0.58
0.51
DES 0.1  0.4
0.0 (0.0–0.0)
0.1  0.4
0.0 (0.0–0.0)
0.1  0.4
0.0 (0.0–0.0)
0.99
0.58
Stent length, mm 23  14 22  14 23  14 0.36
Stent diameter, mm 2.8  1.1 2.8  1.0 2.8  1.1 0.99
Direct stenting 207 (29%) 93 (27%) 114 (32%) 0.16
Initial TIMI ﬂow grade
0 367 (52%) 180 (52%) 187 (52%) 0.55
1 91 (13%) 45 (13%) 46 (13%)
2 139 (20%) 63 (18%) 76 (21%)
3 110 (16%) 60 (17%) 50 (14%)
Final TIMI ﬂow grade
0 9 (1.3%) 6 (1.7%) 3 (0.8%) 0.62
1 7 (1.0%) 4 (1.1%) 3 (0.8%)
2 39 (5.5%) 17 (4.9%) 22 (6.1%)
3 652 (92%) 321 (92%) 331 (92%)
Fluoroscopy, min 8.0  5.1 7.9  4.7 8.0  5.5 0.76
Procedure duration, min 49  19 49  20 49  18 0.95
ACT, s 244  90 247  89 242  90 0.60
Contrast volume, ml 176  66 170  71 182  60 0.0104
Angiographic success 644 (91%) 318 (91%) 326 (91%) 0.79
Technical success 684 (97%) 338 (97%) 346 (96%) 0.67
Closure device 140 (20%) 4 (1.1%) 136 (38%) <0.0001
IABP 5 (0.7%) 2 (0.6%) 3 (0.8%) 1.00
UFH dose, IU 8,613  2,595 8,632  2,715 8,593  2,477 0.84
UFH dose, IU/kg 104  32 103  34 105  31 0.41
Clopidogrel 600-mg loading dose 623 (89%) 313 (91%) 310 (88%) 0.22
ASA 702 (99%) 345 (99%) 357 (99%) 0.68
LMWH 6 (0.8%) 6 (1.7%) 0 (0%) 0.014
Glycoprotein IIb/IIIa inhibitor 317 (45%) 155 (45%) 162 (45%) 0.88
Thrombectomy 200 (28%) 92 (26%) 108 (30%) 0.32
Baseline hemoglobin, g/l 143  14 143  15 143  13 0.97
Baseline creatinine, mg/dl 0.88  0.25 0.90  0.27 0.86  0.22 0.066
Values are n (%), mean  SD, or median (interquartile range).
ACT ¼ activated clotting time; ASA ¼ acetylsalicylic acid; BMS ¼ bare-metal stent(s); Cx ¼ circumﬂex artery; DES ¼ drug-eluting stent(s); IABP ¼
intra-aortic balloon pump; LAD ¼ left anterior descending artery; LMCA ¼ left main coronary artery; LMWH ¼ low-molecular- weight heparin; RCA ¼
right coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction; UFH ¼ unfractionated heparin.
Bernat et al. JACC Vol. 63, No. 10, 2014
The STEMI-RADIAL Trial March 18, 2014:964–72
968vs. 11%, p ¼ 0.0028) (Table 3, Fig. 1). There were no
signiﬁcant differences in the composite endpoint of death,
MI, and stroke (3.5% vs. 4.2%; p ¼ 0.70). The mortality ratewas 2.3% in the radial group versus 3.1% in the femoral group
at 30 days (p ¼ 0.64) and 2.3% versus 3.6% at 6 months
(log-rank p¼ 0.31), respectively (Fig. 4). Individual causes of
Figure 2 Bleeding Events and Vascular Complications
Primary endpoint included major bleeding and vascular complications. Gray ruled bars = femoral; solid bars = radial.
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969death are shown in Online Table 2. Most deaths in both
cohorts resulted from pump failure, with the exception of 3
deaths in the femoral group that stemmed from septic shock
secondary to pulmonary infections or pulmonary embolism.Discussion
The main ﬁndings of the STEMI-RADIAL trial can be
summarized as follows: in patients presenting with STEMI
within 12 h of symptom onset and undergoing primary PCI
by experienced operators, the radial approach signiﬁcantly
reduced major bleeding and severe access site complications
and was associated with a superior net clinical beneﬁt
compared with the femoral approach. Moreover, contrast
volume and duration of stay in the intensive care unit were
also signiﬁcantly reduced with the radial approach.Figure 3 Clinical Outcomes
Net adverse clinical events (NACE) included major adverse cardiovascular events
(MACE) and bleeding/vascular complications. Gray ruled bars = femoral; solid
bars = radial.Primary PCI is the dominant strategy for the treatment
of patients with acute STEMI. As recommended by North
American and European guidelines (Class IA), primary
PCI should be preferred to thrombolysis provided that
patients undergo PCI within 120 min of ﬁrst medical
contact (8,9). Nonetheless, patients undergoing primary
PCI remain at a higher risk of major bleeding compared
with thrombolysis (1). Periprocedural major bleeding is
a strong independent predictor of early and late major
adverse cardiovascular events and mortality (15–19). In an
analysis of over 3 million PCIs from the U.S. national
registry, post-procedural bleeding events were associated
with an increased risk of in-hospital mortality and an
estimated 12.1% death rate related to bleeding complica-
tions (20). Recently, new antithrombin therapy has been
shown to reduce periprocedural major bleeding after
primary PCI, and this has been associated with a signiﬁcant
reduction in mortality at 30 days and up to 3 years (12,21).
However in those trials, the use of the radial approach was
extremely limited.
Periprocedural bleeding can be categorized into access
site and non–access site related. Although non–access site
bleeding confers a worse prognosis than access site–related
bleeding, the latter still represents a signiﬁcant proportion
of bleeding events (19). In patients with acute coronary
syndrome, access site–related bleeding represents 30% of
the total bleeding events, and this value reaches w50%
in STEMI patients (22). Hence, the radial approach,
which virtually eliminates access site–related bleeding, can
directly impact on outcomes after primary PCI for
STEMI.
In the RIVAL-STEMI subgroup, Mehta et al. (7)
showed a 54% relative reduction in 30-day all-cause mor-
tality. However no signiﬁcant reduction in protocol-deﬁned
major bleeding was observed. Better results were associated
with higher-volume centers and radial proﬁcient operators.
Table 3 Clinical Outcomes
Overall
(n ¼ 707)
Radial
(n ¼ 348)
Femoral
(n ¼ 359) p Value
ICU stay 2.8  2.4
2 (2–3)
2.5  1.7
2 (1–3)
3.0  2.9
2 (2–3)
0.0038
0.0016
Death, MI, stroke 27 (3.8%) 12 (3.5%) 15 (4.2%) 0.70
Death, MI, stroke, revascularization 82 (12%) 42 (12%) 40 (11%) 0.73
NACE (death, MI, stroke, major bleeding) 54 (7.6%) 16 (4.6%) 38 (11%) 0.0028
Death
Peri-PCI 2 (0.3%) 1 (0.3%) 1 (0.3%) 1.00
48 h 4 (0.6%) 2 (0.6%) 2 (0.6%) 1.00
30 days 19 (2.7%) 8 (2.3%) 11 (3.1%) 0.64
6 months 21 (3.0%) 8 (2.3%) 13 (3.6%) 0.31
MI
Peri-PCI d d d d
48 h 3 (0.4%) 2 (0.6%) 1 (0.3%) 0.62
30 days 7 (1.0%) 4 (1.2%) 3 (0.8%) 0.72
Stroke
Peri-PCI 1 (0.1%) 0 (0%) 1 (0.3%) 1.00
48 h 2 (0.3%) 1 (0.3%) 1 (0.3%) 1.00
30 days 2 (0.3%) 1 (0.3%) 1 (0.3%) 1.00
CABG/revascularization
Peri-PCI 4 (0.6%) 1 (0.3%) 3 (0.8%) 0.62
48 h 8 (1.1%) 2 (0.6%) 6 (1.7%) 0.29
30 days 60 (8.5%) 32 (9.2%) 28 (7.8%) 0.59
Major bleeding 31 (4.4%) 5 (1.4%) 26 (7.2%) 0.0001
GI bleeding 5 (0.7%) 1 (0.3%) 4 (1.1%) 0.37
Hb drop 4 g/dl without overt bleeding 2 (0.3%) 1 (0.3%) 1 (0.3%) 1.00
Hb drop 3 g/dl with overt bleeding 13 (1.8%) 3 (0.9%) 10 (2.8%) 0.090
Hematoma >15 cm 21 (3.0%) 2 (0.6%) 19 (5.3%) 0.0002
Transfusion (non-CABG) 3 (0.4%) 0 (0%) 3 (0.8%) 0.25
Vascular access complication 4 (0.6%) 1 (0.3%) 3 (0.8%) 0.62
Values are mean  SD, median (interquartile range), or n (%).
CABG ¼ coronary artery bypass graft; GI ¼ gastrointestinal; Hb ¼ hemoglobin; ICU ¼ intensive care unit; MI ¼myocardial infarction; NACE ¼ net
adverse clinical event; PCI ¼ percutaneous coronary intervention.
Figure 4 Survival Curves
Survival curves for radial and femoral groups up to 6 months after primary
percutaneous coronary intervention.
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970In contrast, in the RIFLE-STEACS trial, Romagnoli et al.
(6) observed a 50% relative reduction in cardiac mortality in
parallel with a signiﬁcant reduction in major bleeding.
Nevertheless, causes of mortality were mostly related to
pump failure within the ﬁrst 24 to 48 h after primary PCI.
Hence, the relationship with periprocedural bleeding can
hardly explain such dramatic clinical beneﬁt. The mecha-
nisms by which radial approach can reduce mortality
remain elusive (23). The STEMI population from the
RIVAL trial had a few signiﬁcant issues. There was no
clinical stratiﬁcation according to clinical presentation, and
the STEMI population originated from a post-hoc analysis
of a limited group (28%) of patients from the RIVAL
population. Importantly, in this subgroup, primary PCI was
the preferred reperfusion therapy in only 74% of cases. In
addition, experience of operators with the radial approach
was highly variable (33% to 80%). In the RIFLE-STEACS
trial, patients with symptom duration up to 24 h were
included as well as patients presenting after failed throm-
bolysis or in cardiogenic shock. Experience with the radial
approach required 50% of cases per year. Patients
included in the STEMI-RADIAL trial matched group
patients for whom primary PCI is recommended as ClassIA in current European and North American guidelines.
Therefore, our trial is representative of STEMI patients for
which current guidelines have been established.
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971In our trial, we found a large reduction of major bleeding
and access site complications in the radial group, and this
correlated with a superior clinical beneﬁt. The signiﬁcant
reduction of intensive care unit stay has also been found
in the RIFLE-STEACS trial and has been associated with
earlier hospital discharge. Hence, patient logistics are
simpliﬁed and hospital costs are reduced with the radial
approach. We also found a nonsigniﬁcant 26% relative
reduction in mortality at 30 days and a relative reduction of
36% at 6 months in the radial group. These reductions could
be potentially clinically relevant, but our study was not
powered to assess mortality. It should be noted that some
deaths in the femoral group might have been promoted by
prolonged bed rest compared with earlier ambulation in the
radial group (23). Earlier ambulation could be another
potential mechanism to reduce mortality after PCI and acute
coronary syndromes. Further investigation is required to
evaluate whether the radial approach could be linked with
a reduction in hospital-acquired infections and/or throm-
bophlebitis and pulmonary embolism.
There has been some reluctance to adopt radial access
during primary PCI because of potential problems such as
delayed reperfusion caused by longer patient preparation,
longer time to gain vascular access, and potentially more
difﬁcult catheter manipulation via the radial artery. Our
study clearly demonstrates that for high-volume radial
centers with experienced operators those issues are
eliminated and are irrelevant. Indeed, the crossover rate
from radial to femoral access was lower than in the RIVAL
and RIFLE-STEACS trials. Again, this reinforces that
training is paramount (7,24). It should also be emphasized
that primary PCI has been the preferred reperfusion strategy
in the Czech Republic since the reporting of the PRAGUE
(PRimary Angioplasty in patients transferred from General
community hospitals to specialized PTCA Units with or
without Emergency thrombolysis) and PRAGUE-2 results
10 years ago (25,26). Primary PCI in the country is currently
performed in >90% of all STEMI patients (25). It is routine
that patients are directly transferred by ambulance from the
ﬁeld directly to the catheterization laboratories. This might
explain at least in part our excellent door-to-balloon times.
According to the results from the Czech National Registry
of Coronary Interventions, transradial primary PCI has
increased from <5% in 2005 to almost 50% in 2011 (27).
Study limitations. It remains possible that the use of
bivalirudin could further improve results by reducing non–
access site bleeding, but the pharmacologic agent is not
available in the Czech Republic. Furthermore, most of the
beneﬁt of bivalirudin has been demonstrated in patients
undergoing PCI by the femoral approach (28) and compared
with heparin þ glycoprotein IIb/IIIa inhibitors (29). The
SAFARI-STEMI (Femoral Versus Radial Access for
Primary PCI) (NCT01398254) randomized trial comparing
the radial and femoral approach when using bivalirudin as
background anticoagulant therapy should provide further
insight on background anticoagulation during primary PCIin the future. As the study was not powered to assess
mortality, a type II error remains possible to explain the lack
of signiﬁcant impact on mortality.
Conclusions
In patients with STEMI presenting within 12 h of symptom
onset, the radial approach was associated with signiﬁcantly lower
incidence of major bleeding and access site complications and
superior net clinical beneﬁt. This supports the use of the radial
approach as a ﬁrst choice in primary PCI within experienced
radial centers and following proper training.Acknowledgments
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